Joseph Walter Vazzano Sells 9,035 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) CFO Joseph Walter Vazzano sold 9,035 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $48,698.65. Following the sale, the chief financial officer directly owned 453,631 shares in the company, valued at $2,445,071.09. This trade represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Joseph Walter Vazzano also recently made the following trade(s):

• On Tuesday, July 22nd, Joseph Walter Vazzano sold 1,502 shares of Abeona Therapeutics stock. The shares were sold at an average price of $6.64, for a total transaction of $9,973.28.
• On Wednesday, July 9th, Joseph Walter Vazzano sold 25,411 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.86, for a total transaction of $148,908.46.

Abeona Therapeutics Price Performance

Abeona Therapeutics stock opened at $5.28 on Thursday. Abeona Therapeutics Inc. has a 52-week low of $3.93 and a 52-week high of $7.54. The company has a quick ratio of 6.65, a current ratio of 6.73 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average is $6.41 and its 200 day moving average is $5.92. The company has a market cap of $270.76 million, a price-to-earnings ratio of 7.54 and a beta of 1.43.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $2.10. The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $21.71 million. Sell-side analysts forecast that Abeona Therapeutics Inc. will post -1.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ABEO. Oppenheimer upped their price objective on Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a research report on Friday, August 15th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a report on Monday, August 18th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $19.50.

Institutional Investors Weigh In On Abeona Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ABEO. Creative Planning lifted its stake in shares of Abeona Therapeutics by 43.0% during the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company’s stock worth $81,000 after acquiring an additional 4,305 shares during the last quarter. Ameritas Investment Partners Inc. purchased a new stake in Abeona Therapeutics in the second quarter worth $25,000. Legal & General Group Plc purchased a new stake in Abeona Therapeutics in the second quarter worth $27,000. OMERS ADMINISTRATION Corp lifted its position in shares of Abeona Therapeutics by 11.0% during the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company’s stock worth $344,000 after purchasing an additional 7,155 shares during the last quarter. Finally, Riverwater Partners LLC purchased a new stake in shares of Abeona Therapeutics during the second quarter valued at $62,000. 80.56% of the stock is currently owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.